Previous 10 | Next 10 |
The U.S. Food and Drug Administration (FDA) granted fast track designation to Ayala Pharmaceuticals' ( NASDAQ: AYLA ) AL102 to treat progressing desmoid tumors. AL102 is being evaluated in a phase 2/3 trial called RINGSIDE, interim results from which were repo...
REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers today a...
Ayala Pharma ( NASDAQ: AYLA ) on Monday announced positive interim results from Part A of the ongoing Phase 2/3 clinical trial testing investigational drug AL102 in desmoid tumors. . Desmoid tumors are benign tumors that are often found in the abdomen, shoulders, ...
- Updated interim results from Part A of RINGSIDE show first confirmed partial response (PR) achieved at week 16 and 3 additional unconfirmed PRs over the follow-up period - - Consistent early tumor shrinkage with ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time for another overview of the biggest pre-market stock movers as we see what’s happening on Thursday! We’ve got earnings reports, stock offerings, clini...
REHOVOT, Israel and WILMINGTON, Del., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announce...
Financial Loss Was Less Than Expected. Ayala reported 2Q22 loss of $ 8.2 million or $(0.54) per share, compared with our estimated loss of $10.9 million or $(0.71) per share. The difference was largely due research and development spending of $5.6 million coming in lower than our estimate of $...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The beaten-down stock market has created an opportunity for contrarian investors in short-squeeze stocks. Essentially, bearish traders must borrow the underlying securities which they are pessimistic about. However, bulli...
A small %Biotech company saw its shares trading higher during Tuesday’s session after the company announced its second quarter financial results for 2022. Some financial highlights from the press release were: - Cash and cash equivalents were $20.1 million as of June 30, 2022...
Ayala Pharmaceuticals press release ( NASDAQ: AYLA ): Q2 GAAP EPS of -$0.54 beats by $0.11 . Collaboration revenue was $38 thousand for the second quarter of 2022, as compared to $761 thousand for the corresponding quarter in 2021. Cash Position: Cash and cash equi...
News, Short Squeeze, Breakout and More Instantly...
Ayala Pharmaceuticals Inc. Company Name:
AYLA Stock Symbol:
NASDAQ Market:
Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected to close near end of Q3 2023 REHOVOT...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, today announced that it will present posters on its gamma secretase inhibitors AL102 and AL101 at the European Societ...
Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of 1.2mg once daily Enrollment in Phase 3 continuing as planned REHOVOT, Israel & MONMOUTH JUNCTION, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmace...